Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

IRFAN A AGHA

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1912982489
CMS profile
313330
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$48,937.28

71 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

IRFAN A AGHA

NPI 1912982489 · CMS profile ID 313330

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1912982489?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
IRFAN A AGHA, NPI 1912982489, CMS profile ID 313330. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1912982489?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). IRFAN A AGHA, NPI 1912982489, CMS profile ID 313330. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1912982489?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
IRFAN A AGHA, NPI 1912982489, CMS profile ID 313330, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1912982489?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

71 matching records · $48,937.28 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 71 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–71 of 71.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $361.8004/02/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104701011 CMS
AstraZeneca Pharmaceuticals LP $174.8604/02/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105558378 CMS
AstraZeneca Pharmaceuticals LP $2,400.0003/28/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105516609 CMS
AstraZeneca Pharmaceuticals LP $116.1503/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104407707 CMS
Vifor Pharma, Inc. $15.9203/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124044996 CMS
Aurinia Pharma U.S., Inc. $112.4802/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150674495 CMS
CALLIDITAS THERAPEUTICS US INC. $116.1402/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141510007 CMS
AstraZeneca Pharmaceuticals LP $3,200.0002/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104392435 CMS
AstraZeneca Pharmaceuticals LP $1,200.0002/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104612518 CMS
AstraZeneca Pharmaceuticals LP $26.8102/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105744302 CMS
AstraZeneca Pharmaceuticals LP $118.3502/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104490794 CMS
AstraZeneca Pharmaceuticals LP $361.8002/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104774798 CMS
AstraZeneca Pharmaceuticals LP $15.4802/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105642608 CMS
GlaxoSmithKline, LLC. $1,300.0002/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116249547 CMS
Renalytix AI, Inc. $23.5401/31/2024 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 1116758322 CMS
GlaxoSmithKline, LLC. $25.1301/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116534002 CMS
AstraZeneca Pharmaceuticals LP $17.1401/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105453157 CMS
CALLIDITAS THERAPEUTICS US INC. $2,500.0001/20/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141508575 CMS
Vifor Pharma, Inc. $26.1501/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124038941 CMS
GlaxoSmithKline, LLC. $325.0001/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116349896 CMS
Alexion Pharmaceuticals, Inc. $30.9501/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1094009831 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $17,973.36 30
PY2020 $8,219.08 28
PY2021 $38,461.20 60
PY2022 $92,262.82 141
PY2023 $81,138.28 134
PY2024 $48,937.28 71
PY2025 $127,907.99 108

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $942,849.16 16
PY2024 Principal investigator $496,947.32 28
PY2023 Principal investigator $71,094.25 13
PY2022 Principal investigator $183,039.27 12
PY2021 Principal investigator $133,187.44 67
PY2020 Principal investigator $303,512.75 62
PY2019 Principal investigator $405,788.00 506

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

16 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alexion Pharmaceuticals, Inc. $16,116.25 10/03/2025 Non-covered Recipient Entity
LIBERTY RESEARCH CENTER LP
a phase 3,randomized,double blind,placebo controlled study to evaluate the efficacy and safety of ravulizumab in adult participants with immunoglobulin a nephropathy IgAN No dispute reported 06/30/2026 1185551275
Principal investigator 1 Aurinia Pharma U.S., Inc. $2,500.00 06/18/2025 Non-covered Recipient Entity
Liberty Research Center
LUPKYNIS Registry Study No dispute reported 06/30/2026 1243930812
Principal investigator 1 Novartis Pharmaceuticals Corporation $637,373.29 06/18/2025 Non-covered Recipient Entity
DALLAS RENAL GROUP
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy No dispute reported 06/30/2026 1190303545
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,500.00 05/22/2025 Non-covered Recipient Entity
LIBERTY RESEARCH
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy No dispute reported 06/30/2026 1190311905
Principal investigator 1 Novartis Pharmaceuticals Corporation $63,122.66 04/04/2025 Non-covered Recipient Entity
DALLAS RENAL GROUP
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function No dispute reported 06/30/2026 1190303535
Principal investigator 1 Aurinia Pharma U.S., Inc. $2,979.20 03/12/2025 Non-covered Recipient Entity
Liberty Research Center
LUPKYNIS Registry Study No dispute reported 06/30/2026 1243930926
Principal investigator 1 Travere Therapeutics, Inc. $7,351.00 02/25/2025 Non-covered Recipient Entity
Dallas Renal Group/Liberty Research Center
SPARTACUS No dispute reported 06/30/2026 1244187229
Principal investigator 1 Aurinia Pharma U.S., Inc. $1,060.00 02/19/2025 Non-covered Recipient Entity
Liberty Research Center
LUPKYNIS Registry Study No dispute reported 06/30/2026 1243931022
Principal investigator 1 Novartis Pharmaceuticals Corporation $33,473.42 01/29/2025 Non-covered Recipient Entity
DALLAS RENAL GROUP
A Phase 1/2, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy No dispute reported 06/30/2026 1190303539
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $54,204.05 01/28/2025 Non-covered Recipient Entity
DALLAS RENAL GROUP- DALLAS
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Povetacicept in Adults With Immunoglobulin A Nephropathy (RAINIER) No dispute reported 06/30/2026 1214124412
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $32,815.75 01/27/2025 Non-covered Recipient Entity
DALLAS RENAL GROUP- DALLAS
A Phase 2b, Open-label Study to Evaluate the Efficacy and Safety of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease With or Without Comorbidities That May Independently Contribute to Chronic Kidney Disease No dispute reported 06/30/2026 1214125558
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,708.12 01/22/2025 Non-covered Recipient Entity
DALLAS RENAL GROUP
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function No dispute reported 06/30/2026 1190303537
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,732.00 01/21/2025 Non-covered Recipient Entity
LIBERTY RESEARCH
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients No dispute reported 06/30/2026 1190311907
Principal investigator 1 Novartis Pharmaceuticals Corporation $58,974.86 01/15/2025 Non-covered Recipient Entity
DALLAS RENAL GROUP
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients No dispute reported 06/30/2026 1190303547
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,750.20 01/09/2025 Non-covered Recipient Entity
DALLAS RENAL GROUP
A randomized, double-blind, parallel group, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patients with active lupus No dispute reported 06/30/2026 1190303549
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $16,188.36 01/01/2025 Non-covered Recipient Entity
DALLAS RENAL GROUP- DALLAS
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease No dispute reported 06/30/2026 1214124120